Picture [LSUS] – The Business Web Portal 600x60px
Organisation › Details

Ultimovacs AB

TET Pharma, is a wholly owned daughter company founded by Immuneed in order to support a therapeutic cancer vaccine project based on the patented TET-technology(TM). Immuneed AB, founded in 2014, is a life science biotech company offering a first-in-class, lab-based human whole-blood assay as a specialized service, for detection of immune-related side effects of biopharmaceuticals. The assay can minimize risks related to drug infusion reactions as well as decrease cost for pre-clinical drug development. The customized services are paired with immunological know-how and expertise, enhancing data output and optimally supporting drug development process; linking preclinical data to clinical reality(TM). *


Period Start 2018-07-01 renamed
  Group Ultimovacs (Group)
  Predecessor TET Pharma (SE)
Products Industry cancer vaccine
  Industry 2 TET-platform™ technology
Person Person Ekström, Gunilla (Immuneed 201808– CEO of 100% sub TET Pharma before CEO of Immuneed AB)
Region Region Uppsala
  Country Sweden
  City n. a. Uppsala
    Address record changed: 2018-09-02
Basic data Employees A: 1 to 10 (2018-08-30)
    * Document for �About Section�: Immuneed AB. (8/28/18). "Press Release: Immuneed AB Appoints New CEO to Strengthen Immuno-service Business Growth and Expansion". Uppsala.
Record changed: 2018-09-02


Picture [LSA] – The Business Web Portal 650x89px

More documents for Ultimovacs (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top